Clinical Trials Browser

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, B-Cell, Neurotoxicity Syndromes

NCT05025826 2025-12-02

PROPERTY

Phase NA Active not recruiting

110 enrolled

Gastrointestinal

Stomach Neoplasms, Neurotoxicity Syndromes

NCT04150913 2025-11-25

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Phase 2 Completed

15 enrolled 17 charts

Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Neurotoxicity Syndromes

NCT00727922 2025-11-20

MnDPDP-K04

Phase 2 Completed

23 enrolled

Neoplasms, Neurotoxicity Syndromes

NCT04583124 2025-11-18

ATENTO

Phase NA Completed

42 enrolled

Breast

Breast Neoplasms, Neurotoxicity Syndromes

NCT00978458 2025-09-08

Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

Phase 3 Active not recruiting

540 enrolled

CNS

Astrocytoma, Brain Neoplasms, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Neurotoxicity Syndromes

NCT06950190 2025-08-12

(ECCPC)

Phase 3 Enrolling by invitation

100 enrolled

Chemotherapy-Related Cognitive Impairment, Neurotoxicity Syndromes, Cognitive Dysfunction

Clinical Trials

CHEMOVES

CARE-T

Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer

Assessing DCog Short for Neurotoxicity in CAR-T

o Tadalafil for Prevention of Docetaxel-Induced Peripheral Neuropathy in Prostate Cancer

Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel

Neuroprotective Effect of Neurotropin on Chronic OXA-induced Neurotoxicity in Stage II and Stage III CRC Patients

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma